Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khong Y Ng

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|January 17, 2017
Rosette Assay: Highly Customizable Dot-Blot for SH2 Domain ScreeningKhong Y Ng, Kazuya Machida
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2010
Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromesStormy J Chamberlain, Pin-Fang Chen, Khong Y Ng, et al.
Blood Cancer Discovery|October 22, 2020
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaCarlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|January 17, 2017
Rosette Assay: Highly Customizable Dot-Blot for SH2 Domain ScreeningKhong Y Ng, Kazuya Machida
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2010
Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromesStormy J Chamberlain, Pin-Fang Chen, Khong Y Ng, et al.
Blood Cancer Discovery|October 22, 2020
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaCarlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Pageof 1